Xiaflex

Tweet

Peyronie’s disease - unhealthy bending of the penis - is associated with Dupuytren’s contracture, hence the “penis-straightening.”

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) filed by its partner Auxilium Pharmaceuticals, Inc. for the use of XIAFLEX(TM) for the treatment of Dupuytren’s disease, a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers. The BLA acceptance triggers a milestone payment to BioSpecifics under our agreement with Auxilium.

BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytren’s Disease

As with all drugs there are complications:

Xiaflex, the penis-straightening drug being developed by Auxilium for Pfizer, causes “a lot of different reactions such as swelling and redness and bruising” in some patients, according to Auxilium chief medical officer Anthony DelConte.

Pfizer’s Penis-Straightening Drug May Cause “Swelling, Redness and Bruising”